Teemu Daniel Laajala

Teemu Daniel Laajala

Auto-generated profile, based on publicly available information

Teemu Daniel Laajala

Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland; iCAN-Digital Precision Cancer Medicine Flagship, Helsinki, Finland; Department of Mathematics and Statistics, University of Turku, Turku, Finland

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2014 in Diabetes
Verified
Journal Article
Open access
PDF file
HKHenna Kallionpää
Henna Kallionpää
LELaura L. Elo
Laura L. Elo
ELEssi Laajala
Essi Laajala
JMJuha Mykkänen
Juha Mykkänen
IRIsis Ricaño-Ponce
Isis Ricaño-Ponce
RLRiitta Lahesmaa
Riitta Lahesmaa
The insult leading to autoantibody development in children who will progress to develop type 1 diabetes (T1D) has remained elusive. To investigate the genes and molecular pathways in the pathogenesis of this disease, we performed genome-wide transcriptomics analysis on a unique series of prospective whole-blood RNA samples from at-risk children collected in the Finnish Type 1 Diabetes Prediction and Prevention study. We studied 28 autoantibody-positive children, out of which 22 progressed to clinical disease. Collectively, the samples covered the time span from before the development of autoantibodies (seroconversion) through the diagnosis of diabetes. Healthy control subjects matched for date and place of birth, sex, and HLA-DQB1 susceptibility were selected for each case. Additionally, we genotyped the study subjects with Immunochip to identify potential genetic variants associated with the observed transcriptional signatures. Genes and pathways related to innate immunity functions, such as the type 1 interferon (IFN) response, were active, and IFN response factors were identified as central mediators of the IFN-related transcriptional changes. Importantly, this signature was detected already before the T1D-associated autoantibodies were detected. Together, these data provide a unique resource for new hypotheses explaining T1D biology.

4 July 2018 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MRMaija Ruuth
Maija Ruuth
SNSu Duy Nguyen
Su Duy Nguyen
TVTerhi Vihervaara
Terhi Vihervaara
MHMika Hilvo
Mika Hilvo
TLTeemu D Laajala
Teemu D Laajala
KÖKatariina Öörni
Katariina Öörni
Low-density lipoprotein (LDL) particles cause atherosclerotic cardiovascular disease (ASCVD) through their retention, modification, and accumulation within the arterial intima. High plasma concentrations of LDL drive this disease, but LDL quality may also contribute. Here, we focused on the intrinsic propensity of LDL to aggregate upon modification. We examined whether inter-individual differences in this quality are linked with LDL lipid composition and coronary artery disease (CAD) death, and basic mechanisms for plaque growth and destabilization. We developed a novel, reproducible method to assess the susceptibility of LDL particles to aggregate during lipolysis induced ex vivo by human recombinant secretory sphingomyelinase. Among patients with an established CAD, we found that the presence of aggregation-prone LDL was predictive of future cardiovascular deaths, independently of conventional risk factors. Aggregation-prone LDL contained more sphingolipids and less phosphatidylcholines than did aggregation-resistant LDL. Three interventions in animal models to rationally alter LDL composition lowered its susceptibility to aggregate and slowed atherosclerosis. Similar compositional changes induced in humans by PCSK9 inhibition or healthy diet also lowered LDL aggregation susceptibility. Aggregated LDL in vitro activated macrophages and T cells, two key cell types involved in plaque progression and rupture. Our results identify the susceptibility of LDL to aggregate as a novel measurable and modifiable factor in the progression of human ASCVD.

18 July 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
OKOtto Kauko
Otto Kauko
COCaitlin M. O’connor
Caitlin M. O’connor
EKEvgeny Kulesskiy
Evgeny Kulesskiy
JSJaya Sangodkar
Jaya Sangodkar
AAAnna Aakula
Anna Aakula
Jukka WestermarckJukka Westermarck
Jukka Westermarck
Pharmacological PP2A activation is a druggable approach to overcome MEK inhibitor resistance.

1 January 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
JGJustin Guinney
Justin Guinney
TWTao Wang
Tao Wang
TLTeemu D Laajala
Teemu D Laajala
KWKimberly Kanigel Winner
Kimberly Kanigel Winner
JBJ Christopher Bare
J Christopher Bare
YZYuxin Zhu
Yuxin Zhu

18 December 2009 in BMC Genomics
Verified
Journal Article
Open access
PDF file
TLTeemu D Laajala
Teemu D Laajala
SRSunil Raghav
Sunil Raghav
STSoile Tuomela
Soile Tuomela
RLRiitta Lahesmaa
Riitta Lahesmaa
TATero Aittokallio
Tero Aittokallio
LELaura L Elo
Laura L Elo
Background: Chromatin immunoprecipitation coupled with massively parallel sequencing (ChIP-seq) is increasingly being applied to study transcriptional regulation on a genome-wide scale. While numerous algorithms have recently been proposed for analysing the large ChIP-seq datasets, their relative merits and potential limitations remain unclear in practical applications. Results: The present study compares the state-of-the-art algorithms for detecting transcription factor binding sites in four diverse ChIP-seq datasets under a variety of practical research settings. First, we demonstrate how the biological conclusions may change dramatically when the different algorithms are applied. The reproducibility across biological replicates is then investigated as an internal validation of the detections. Finally, the predicted binding sites with each method are compared to high-scoring binding motifs as well as binding regions confirmed in independent qPCR experiments. Conclusions: In general, our results indicate that the optimal choice of the computational approach depends heavily on the dataset under analysis. In addition to revealing valuable information to the users of this technology about the characteristics of the binding site detection approaches, the systematic evaluation framework provides also a useful reference to the developers of improved algorithms for ChIP-seq data.

24 May 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
FJFlorus C de Jong
Florus C de Jong
TLTeemu D. Laajala
Teemu D. Laajala
RHRobert F. Hoedemaeker
Robert F. Hoedemaeker
KJKimberly Jordan
Kimberly Jordan
AMAngelique C. J. van der Made
Angelique C. J. van der Made
Tahlita ZuiverloonTahlita Zuiverloon
Tahlita Zuiverloon
The recommended treatment for patients with high-risk non–muscle-invasive bladder cancer (HR-NMIBC) is tumor resection followed by adjuvant Bacillus Calmette-Guérin (BCG) bladder instillations. However, only 50% of patients benefit from this therapy. If progression to advanced disease occurs, then patients must undergo a radical cystectomy with risks of substantial morbidity and poor clinical outcome. Identifying tumors unlikely to respond to BCG can translate into alternative treatments, such as early radical cystectomy, targeted therapies, or immunotherapies. Here, we conducted molecular profiling of 132 patients with BCG-naive HR-NMIBC and 44 patients with recurrences after BCG (34 matched), which uncovered three distinct BCG response subtypes (BRS1, 2 and BRS3). Patients with BRS3 tumors had a reduced recurrence-free and progression-free survival compared with BRS1/2. BRS3 tumors expressed high epithelial-to-mesenchymal transition and basal markers and had an immunosuppressive profile, which was confirmed with spatial proteomics. Tumors that recurred after BCG were enriched for BRS3. BRS stratification was validated in a second cohort of 151 BCG-naive patients with HR-NMIBC, and the molecular subtypes outperformed guideline-recommended risk stratification based on clinicopathological variables. For clinical application, we confirmed that a commercially approved assay was able to predict BRS3 tumors with an area under the curve of 0.87. These BCG response subtypes will allow for improved identification of patients with HR-NMIBC at the highest risk of progression and have the potential to be used to select more appropriate treatments for patients unlikely to respond to BCG.